1-20 of 51
David M. Nanus
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract CT127: Pre-operative abemaciclib in localized cisplatin-ineligible MIBC with tissue and ctDNA molecular response validation (CLONEVO)

Free
Bishoy M. Faltas, Mohamed Osman, Mark G. Evans, Daniel J. Margolis, Cora N. Sternberg, Jones T. Nauseef, Ana M. Molina, David M. Nanus, Neal A. Patel, Rohit K. Jain, Amie Patel, Michael Sigouros, Jyothi Manohar, Hiranmayi Ravichandran, Amanda Reid, Majd Al Assaad, Giovanni Medico, Giorgio Inghirami, Benjamin D. Hopkins, Juan Miguel Mosquera, Philip Abbosh, Manuel Hidalgo, William F. Hooper, Nicolas Robine, Olivier Elemento, Namrata Peswani, Suzanne Cole, Douglas S. Scherr, Scott T. Tagawa
Journal: Cancer Research
Cancer Res (2025) 85 (8_Supplement_2): CT127.
https://doi.org/10.1158/1538-7445.AM2025-CT127
Published: 25 April 2025
View articletitled, Abstract CT127: Pre-operative abemaciclib in localized cisplatin-ineligible MIBC with tissue and ctDNA molecular response validation (CLONEVO)
Journal Articles

Abstract 7369: Self-reported barriers to healthcare and cancer screening rates: results from the All of Us Research Program

Free
Kevin H. Kensler, Anjile An, Aaron Gurayah, Faith Morley, Meenakshi Davuluri, David M. Nanus, Bashir Al Hussein Al Awamlh, Rulla M. Tamimi
Journal: Cancer Research
Cancer Res (2025) 85 (8_Supplement_1): 7369.
https://doi.org/10.1158/1538-7445.AM2025-7369
Published: 21 April 2025
View articletitled, Abstract 7369: Self-reported barriers to healthcare and cancer screening rates: results from the All of Us Research Program
Journal Articles

Abstract 1645: Developing first-in-class AR-V7/AR-fl molecular glue degrader to revolutionize prostate cancer therapeutics

Free
CheukMan Cherie Au, Michelle Naidoo, Catrina Estrella, Prerna Vatsa, Ying Wang, Zhao Wang, David M. Nanus, Urko del Castillo, Paraskevi Giannakakou
Journal: Cancer Research
Cancer Res (2025) 85 (8_Supplement_1): 1645.
https://doi.org/10.1158/1538-7445.AM2025-1645
Published: 21 April 2025
View articletitled, Abstract 1645: Developing first-in-class AR-V7/AR-fl molecular glue degrader to revolutionize prostate cancer therapeutics
Journal Articles

Abstract CT225: Quantitative assessment of PSMA imaging before and after 177Lu-PSMA-617 treatment in a Ph I/II trial

Free
Jones Trevor Nauseef, Charlene Thomas, Michael Sun, Nicole Jacobs, Andrés Ricaurte Fajardo, Sam Ruder, Escarleth Fernandez, Zachary Davidson, Amie Patel, A. Oliver Sartor, Shankar Vallabhajosula, Ana Molina, Cora N. Sternberg, David M. Nanus, Sandra Huicochea Castellanos, Joseph Osborne, Neil H. Bander, Timothy Perk, Scott Tagawa
Journal: Cancer Research
Cancer Res (2024) 84 (7_Supplement): CT225.
https://doi.org/10.1158/1538-7445.AM2024-CT225
Published: 05 April 2024
View articletitled, Abstract CT225: Quantitative assessment of PSMA imaging before and after 177Lu-PSMA-617 treatment in a Ph I/II trial
Journal Articles

Abstract 1231: First-in-class AR-V7/AR-fl small molecule molecular glue degrader for prostate cancer treatment

Free
CheukMan C. Au, Catrina Estrella, Prerna Vatsa, Michelle Naidoo, Michael Miller, Peter T. Meinke, David M. Nanus, Paraskevi Giannakakou
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 1231.
https://doi.org/10.1158/1538-7445.AM2024-1231
Published: 22 March 2024
View articletitled, Abstract 1231: First-in-class AR-V7/AR-fl small molecule molecular glue degrader for prostate cancer treatment
Journal Articles

Abstract CT014: Phase I dose-escalation study of fractionated dose 225Ac J591 for metastatic castration resistant prostate cancer

Free
Jones T. Nauseef, Michael Sun, Charlene Thomas, Mahelia Bissassar, Escarleth Fernandez, Zachary Davidson, Amie Patel, Angela Tan, Tessa A. Chamberlain, Kara Earle, Rebecca Wunder, Sabrina Guervil, Sandra H. Castellanos, Judith Stangl-Kremser, Peter S. Gregos, Joseph R. Osborne, Karla V. Ballman, Ana M. Molina, Cora N. Sternberg, David M. Nanus, Neil H. Bander, Scott T. Tagawa
Journal: Cancer Research
Cancer Res (2023) 83 (8_Supplement): CT014.
https://doi.org/10.1158/1538-7445.AM2023-CT014
Published: 14 April 2023
View articletitled, Abstract CT014: Phase I dose-escalation study of fractionated dose 225Ac J591 for metastatic castration resistant prostate cancer
Journal Articles

Abstract 646: Liquid biopsy transcriptomics identify pathways associated with poor outcomes and immune phenotypes in men with mCRPC

Free
Jiaren Zhang, Bob Zimmermann, Giuseppe Galletti, Susan Halabi, Ada Gjyrezi, Qian Yang, Santosh Gupta, Akanksha Verma, Andrea Sboner, Monika Anand, Daniel J. George, Simon G. Gregory, Prerna Mahtani, Seunghee Hong, Virginia Pascual, Clio P. Mavragani, Emmanuel S. Antonarakis, David M. Nanus, Scott T. Tagawa, Olivier Elemento, Andrew J. Armstrong, Paraskevi Giannakakou
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 646.
https://doi.org/10.1158/1538-7445.AM2022-646
Published: 15 June 2022
View articletitled, Abstract 646: Liquid biopsy transcriptomics identify pathways associated with poor outcomes and immune phenotypes in men with mCRPC
Journal Articles

Abstract CT143: Results of combined targeting of prostate-specific membrane antigen (PSMA) with alpha-radiolabeled antibody 225Ac-J591 and beta-radiolabeled ligand 177Lu-PSMA I&T: preclinical and initial phase 1 clinical data in patients with metastatic castration-resistant prostate cancer (mCRPC)

Free
Scott T. Tagawa, Edward Fung, Muhammad O. Niaz, Mahelia Bissassar, Sharon Singh, Amie Patel, Angela Tan, Juana Martinez Zuloaga, Sandra Huicochea Castellanos, Jones T. Nauseef, Ana Molina, Cora Sternberg, David M. Nanus, Joseph Osborne, Neil H. Bander
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): CT143.
https://doi.org/10.1158/1538-7445.AM2022-CT143
Published: 15 June 2022
View articletitled, Abstract CT143: Results of combined targeting of prostate-specific membrane antigen (PSMA) with alpha-radiolabeled antibody 225Ac-J591 and beta-radiolabeled ligand 177Lu-PSMA I&T: preclinical and initial phase 1 clinical data in patients with metastatic castration-resistant prostate cancer (mCRPC)
Journal Articles

Abstract 1264: CTC-based biomarker analysis and correlation with clinical response to PSMA-TRT in mCRPC

Free
Giuseppe Galletti, Prerna Vatsa, Joseph R. Osborne, Neil H. Bander, David M. Nanus, Scott T. Tagawa, Paraskevi Giannakakou
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 1264.
https://doi.org/10.1158/1538-7445.AM2022-1264
Published: 15 June 2022
View articletitled, Abstract 1264: CTC-based biomarker analysis and correlation with clinical response to PSMA-TRT in mCRPC
Journal Articles

Abstract CT122: Phase I dose-escalation study of prostate-specific membrane antigen (PSMA)-targeted alpha emitter 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC)

Free
Scott T. Tagawa, Joseph Osborne, Charlene Thomas, Escarleth Fernandez, Muhammad J. Niaz, Shankar Vallabhajosula, Panagiotis Vlachostergios, Ana M. Molina, Cora Sternberg, Sharon Singh, Amie Patel, Angela Tan, John Babich, David M. Nanus, Karla Ballman, Neil H. Bander
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): CT122.
https://doi.org/10.1158/1538-7445.AM2020-CT122
Published: 15 August 2020
View articletitled, Abstract CT122: Phase I dose-escalation study of prostate-specific membrane antigen (PSMA)-targeted alpha emitter 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC)
Journal Articles

Abstract 6511: Androgen receptor (AR) genomic alterations and clinical outcome with prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy

Free
Michael Sun, Muhammad Niaz, Charlene Thomas, Ariel Schaap, Kristine Lacuna, Panagiotis Vlachostergios, Paul Christos, Ana M. Molina, David M. Nanus, Cora N. Sternberg, Joseph Osborne, Neil H. Bander, Scott T. Tagawa
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 6511.
https://doi.org/10.1158/1538-7445.AM2020-6511
Published: 15 August 2020
View articletitled, Abstract 6511: Androgen receptor (AR) genomic alterations and clinical outcome with prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy
Journal Articles

Abstract 4865: Prognostic value of BRCA2 and AR gene alterations in advanced prostate cancer patients treated with PSMA-targeted radionuclide therapies

Free
Panagiotis J. Vlachostergios, Vincenza Conteduca, Amy L. Hackett, Jyothi Manohar, Aileen Lee, Aidan Case, Michael Sun, Muhammad J. Niaz, Olivier Elemento, Ana M. Molina, David M. Nanus, Himisha Beltran, Neil H. Bander, Scott T. Tagawa
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 4865.
https://doi.org/10.1158/1538-7445.AM2019-4865
Published: 01 July 2019
View articletitled, Abstract 4865: Prognostic value of BRCA2 and AR gene alterations in advanced prostate cancer patients treated with PSMA-targeted radionuclide therapies
Journal Articles

Abstract CT097: Phase I trial of apalutamide plus abiraterone acetate, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC)

Free
Ana Molina, Paul Christos, Amy Hackett, Luke Nordquist, Edward Gelmann, Mark Stein, Cora Sternberg, Himisha Beltran, Lauren Gracey, Giuseppe Galletti, Paraskevi Giannakakou, David M. Nanus, Scott T. Tagawa
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): CT097.
https://doi.org/10.1158/1538-7445.AM2019-CT097
Published: 01 July 2019
View articletitled, Abstract CT097: Phase I trial of apalutamide plus abiraterone acetate, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC)
Journal Articles

Abstract 1947: Rovalpituzumab tesirine as a therapeutic agent for neuroendocrine prostate cancer

Free
Loredana Puca, Verena Sailor, Katie Gavyert, Etienne Dardenne, Kumiko Isse, Michael Sigouros, David M. Nanus, Scott T. Tagawa, Juan Miguel Mosquera, Laura Saunders, Himisha Beltran
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 1947.
https://doi.org/10.1158/1538-7445.AM2018-1947
Published: 01 July 2018
View articletitled, Abstract 1947: Rovalpituzumab tesirine as a therapeutic agent for neuroendocrine prostate cancer
Journal Articles

Abstract 426: Variant allele frequency changes and treatment responses in advanced prostate cancer

Free
Panagiotis J. Vlachostergios, Ana M. Molina, David M. Nanus, Himisha Beltran, Scott T. Tagawa
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 426.
https://doi.org/10.1158/1538-7445.AM2018-426
Published: 01 July 2018
View articletitled, Abstract 426: Variant allele frequency changes and treatment responses in advanced prostate cancer
Journal Articles

Abstract NG06: Genomic dissection of the clonal evolution dynamics of chemotherapy-resistant urothelial carcinoma

Free
Bishoy M. Faltas, Davide Prandi, Scott T. Tagawa, Ana M. Molina, David M. Nanus, Cora Sternberg, Jonathan Rosenberg, Juan Miguel Mosquera, Brian Robinson, Olivier Elemento, Andrea Sboner, Himisha Beltran, Francesca Demichelis, Mark A. Rubin
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): NG06.
https://doi.org/10.1158/1538-7445.AM2017-NG06
Published: 01 July 2017
View articletitled, Abstract NG06: Genomic dissection of the clonal evolution dynamics of chemotherapy-resistant urothelial carcinoma
Journal Articles

Abstract 2736: A digital droplet PCR assay for the quantitation of androgen receptor and splice variant expression in CTCs from metastatic castration resistant prostate cancer patients

Free
Ada Gjyrezi, Giuseppe Galletti, Areti Strati, Seaho Kim, Evi Lianidou, David M. Nanus, Jun Luo, Emmanuel Antonarakis, Scott T. Tagawa, Andrew Armstrong, Paraskevi Giannakakou
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 2736.
https://doi.org/10.1158/1538-7445.AM2017-2736
Published: 01 July 2017
View articletitled, Abstract 2736: A digital droplet PCR assay for the quantitation of androgen receptor and splice variant expression in CTCs from metastatic castration resistant prostate cancer patients
Journal Articles

Abstract CT140: Pilot study of “hyperfractionated” anti-prostate specific membrane antigen (PSMA) radioimmunotherapy (177Lu-J591) for progressive metastatic castration-resistant prostate cancer (mCRPC)

Free
Ana M. Molina, Jaspreet S. Batra, Beerinder S. Karir, Yuliya Jhanwar, Shankar Vallabhajosula, Paul J. Christos, Linda Lam, Jennifer Epstein, Irene Karpenko, Himisha Beltran, David M. Nanus, Stanley J. Goldsmith, Neil H. Bander, Scott T. Tagawa
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): CT140.
https://doi.org/10.1158/1538-7445.AM2016-CT140
Published: 15 July 2016
View articletitled, Abstract CT140: Pilot study of “hyperfractionated” anti-prostate specific membrane antigen (PSMA) radioimmunotherapy (177Lu-J591) for progressive metastatic castration-resistant prostate cancer (mCRPC)
Journal Articles

Abstract 4971: Quantitative image analysis of androgen receptor (AR) and tubulin biomarker profiles in circulating tumor cells (CTCs) from metastatic castration resistant prostate cancer (mCRPC) patients

Free
Daniel Worroll, Giuseppe Galletti, David M. Nanus, Scott T. Tagawa, Paraskevi Giannakakou
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 4971.
https://doi.org/10.1158/1538-7445.AM2016-4971
Published: 15 July 2016
View articletitled, Abstract 4971: Quantitative image analysis of androgen receptor (AR) and tubulin biomarker profiles in circulating tumor cells (CTCs) from metastatic castration resistant prostate cancer (mCRPC) patients
Journal Articles

Abstract 3971: Non-invasive assessment of prostate-specific membrane antigen (PSMA) expression as a prognostic marker in men with metastatic castration-resistant prostate cancer (mCRPC)

Free
Kavya Pinto-Chengot, Yuliya Jhanwar, Jaspreet Batra, Beerinder Karir, Shankar Vallabhajosula, Paul Christos, Ana Molina, Himisha Beltran, David M. Nanus, Stanley J. Goldsmith, Neil H. Bander, Scott T. Tagawa
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 3971.
https://doi.org/10.1158/1538-7445.AM2016-3971
Published: 15 July 2016
View articletitled, Abstract 3971: Non-invasive assessment of prostate-specific membrane antigen (PSMA) expression as a prognostic marker in men with metastatic castration-resistant prostate cancer (mCRPC)